A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC

NCT04736823 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

265

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC

Interventions

DRUG: AK112
DRUG: Pemetrexed
DRUG: Paclitaxel
DRUG: Carboplatin
DRUG: Docetaxel

Sponsor

Akeso